Onconic Therapeutics Announces Positive Phase 3 Results for JAQBO at Digestive Diseases Week 2024

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Onconic-Therapeutics

More Like This

PR Newswire associated0

Onconic Therapeutics Receives MFDS Approval for JAQBO, a New Treatment for Gastroesophageal Reflux Disease (GERD)

BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026

BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer

PR Newswire associated0

Global Registrational Phase III Study of Olverembatinib for the Treatment of Patients with SDH-Deficient GIST Approved by the China CDE

PR Newswire associated0

Qilu Pharmaceutical Showcases QL1706 Clinical Trial Outcomes in Oral Presentation at ESGO 2024

BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026

Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment